When Khadisha Thornhill asked her doctor in early 2018 for a medical cannabis prescription to deal with the emergence of a serious shoulder injury, it did not go well.

“He kiboshed the idea and made me feel like I was asking for a back alley deal,” recalls the co-founder of Afro Cannada Budsistas, who had previously only consumed cannabis socially while in college.

RYAH Medtech, Inc. subsidiary of RYAH Group, Inc has received a Health Canada medical device license for its proprietary internet of things powered medical cannabis inhaler, proprietary cartridges and software application associated with the device.

This Black Mental Health Day, the Mental Health Commission of Canada (MHCC) highlights a need for greater knowledge of cannabis use and mental health for Black communities in Canada. To discuss cannabis use and mental health in Black communities is to discuss systemic racism and related structural issues in Canadian society.

Today Pure Sunfarms Corp. (“Pure Sunfarms”), a wholly-owned subsidiary of Village Farms International, Inc. (Nasdaq: VFF), announces it, together with its partner NOYA Cannabis Inc (“NOYA”), has launched C brand concentrates in Canada using Cookies flower and genetics. (View original article here)

Working with genetics from NOYA, the exclusive cultivation and processing partner of Cookies in Canada, Pure Sunfarms has grown and processed Cookies strains into cannabis concentrates. The initial offering includes GP20 Diamonds, GP20 Sauce, Georgia P Diamonds, and Georgia P Sauce now available in Ontario.

• CULTURE AND CATHOLIC CANINE – HEXO CORPORATIONs are engaged in manufacturing and marketing cannabis.
• The Columbia Care Corporation (OTC: CCHWF) is a pharmacy company specializing in home medications.
• HBORF, or Harborside Financial (OTC: HBORF) is traded on the OTC market.
• Cronos Group Inc. (NASDAQ: CRON).
• Financial (OTC: FFNTF) by Front Ventures

There are also businesses cashing in on Canada’s successful market for legalized marijuana beyond cannabis shops and cultivation operations. Furthermore, government and industry reports indicate that ancillary home-growing businesses are doing quite well as well.

"We were inundated with emails from people all over Canada from all different walks of life"

A few months before the pandemic began, Rob Whitley, an associate professor of psychiatry at McGill University, applied for funding from the Mental Health Commission of Canada.His goal was to produce three short documentaries over a two-year period focused on cannabis and mental health and how the plant can affect well-being and quality of life. Initially, the scope of the project was concentrated on Montreal but COVID-19 changed those plans.

Preliminary findings hint that treatment “is safe and potentially efficacious for treating cannabis use disorder in schizophrenia.”

Canadian researchers exploring what impact brain stimulation may have on people with schizophrenia — who, as a group, have a high rate of cannabis use disorder (CUD) — found the approach is associated with reduced marijuana use and might prove a treatment for CUD.